Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 49 of the 49 references it cites were found in a registry or an index.

Muscle Mitochondrial ATP Synthesis and Glucose Transport/Phosphorylation in Type 2 Diabetes

Open access
Szendroedi, Julia, Schmid, Albrecht I, Chmelik, Marek, Toth, Christian, Brehm, Attila, Krssak, Martin, Nowotny, Peter, Wolzt, Michael, Waldhausl, Werner, Roden, Michael · 2007 · PLoS Medicine

Abstract

BACKGROUND: Muscular insulin resistance is frequently characterized by blunted increases in glucose-6-phosphate (G-6-P) reflecting impaired glucose transport/phosphorylation. These abnormalities likely relate to excessive intramyocellular lipids and mitochondrial dysfunction. We hypothesized that alterations in insulin action and mitochondrial function should be present even in nonobese patients with well-controlled type 2 diabetes mellitus (T2DM). METHODS AND FINDINGS: We measured G-6-P, ATP synthetic flux (i.e., synthesis) and lipid contents of skeletal muscle with (31)P/(1)H magnetic resonance spectroscopy in ten patients with T2DM and in two control groups: ten sex-, age-, and body mass-matched elderly people; and 11 younger healthy individuals. Although insulin sensitivity was lower in patients with T2DM, muscle lipid contents were comparable and hyperinsulinemia increased G-6-P by 50% (95% confidence interval [CI] 39%-99%) in all groups. Patients with diabetes had 27% lower fasting ATP synthetic flux compared to younger controls (p = 0.031). Insulin stimulation increased ATP synthetic flux only in controls (younger: 26%, 95% CI 13%-42%; older: 11%, 95% CI 2%-25%), but failed to increase even during hyperglycemic hyperinsulinemia in patients with T2DM. Fasting free fatty acids and waist-to-hip ratios explained 44% of basal ATP synthetic flux. Insulin sensitivity explained 30% of insulin-stimulated ATP synthetic flux. CONCLUSIONS: Patients with well-controlled T2DM feature slightly lower flux through muscle ATP synthesis, which occurs independently of glucose transport /phosphorylation and lipid deposition but is determined by lipid availability and insulin sensitivity. Furthermore, the reduction in insulin-stimulated glucose disposal despite normal glucose transport/phosphorylation suggests further abnormalities mainly in glycogen synthesis in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0040154

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Plasma Glucose, Insulin and FFAs Time course of plasma glucose (top), insulin (middle), and FFAs (bottom) concentrations during euglycemic (approximately 5.5 mM glucose) –hyperinsulinemic (approximately 500 pM insulin) clamps in patients with T2DM (n = 10) (diamonds), age- and BMI-matched controls (CONo; n = 10) (squares), and young healthy controls (CONy; n = 11) (triangles). All units expressed as means ± SD. * p < 0.05 T2DM versus controls.
Figure 1 Plasma Glucose, Insulin and FFAs Time course of plasma glucose (top), insulin (middle), and FFAs (bottom) concentrations during euglycemic (approximately 5.5 mM glucose) –hyperinsulinemic (approximately 500 pM insulin) clamps in patients with T2DM (n = 10) (diamonds), age- and BMI-matched controls (CONo; n = 10) (squares), and young healthy controls (CONy; n = 11) (triangles). All units expressed as means ± SD. * p < 0.05 T2DM versus controls.CC BY · PubMed Central
Figure 2 Glucose Metabolism and Intracellular Lipids of Skeletal Muscle and Liver Whole-body glucose disposal (A) and ΔEGP (B) during euglycemic–hyperinsulinemic clamp (n = 31). IMCL in skeletal muscle (n = 31) (C) and liver (n = 29) (HCL) (D). Patients with T2DM (black columns), CONo (grey columns), and CONy (white columns). All results are means ± SD. ¶ p < 0.001 T2DM versus CONy; † p < 0.01 CONo versus T2DM and CONy; * p < 0.05 T2DM versus CONy; § p < 0.001 T2DM versus controls.
Figure 2 Glucose Metabolism and Intracellular Lipids of Skeletal Muscle and Liver Whole-body glucose disposal (A) and ΔEGP (B) during euglycemic–hyperinsulinemic clamp (n = 31). IMCL in skeletal muscle (n = 31) (C) and liver (n = 29) (HCL) (D). Patients with T2DM (black columns), CONo (grey columns), and CONy (white columns). All results are means ± SD. ¶ p < 0.001 T2DM versus CONy; † p < 0.01 CONo versus T2DM and CONy; * p < 0.05 T2DM versus CONy; § p < 0.001 T2DM versus controls.CC BY · PubMed Central
Figure 3 Rates of ATP Synthetic Flux Rates of ATP synthetic flux (means ± SD) during fasting (bfATP, full columns) and during insulin stimulation (ifATP, hatched columns). Patients with T2DM (black columns), CONo controls (grey columns) and CONy controls (white columns) (n = 31). § p < 0.05 T2DM versus CONy; *, p < 0.05; †, p < 0.01.
Figure 3 Rates of ATP Synthetic Flux Rates of ATP synthetic flux (means ± SD) during fasting (bfATP, full columns) and during insulin stimulation (ifATP, hatched columns). Patients with T2DM (black columns), CONo controls (grey columns) and CONy controls (white columns) (n = 31). § p < 0.05 T2DM versus CONy; *, p < 0.05; †, p < 0.01.CC BY · PubMed Central
Figure 4 Associations between ATP Synthetic Flux and Metabolic Parameters Correlation analyses of rates of ATP synthetic flux (n = 31). (A) Relation between fasting plasma concentration of FFAs and bfATP across all groups. (B) Relation between fasting plasma FFAs and ifATP across all groups. Patients with T2DM (n = 10) (diamonds), age- and BMI-matched controls (CONo; n = 10) (squares), and young healthy controls (CONy; n = 11) (triangles).
Figure 4 Associations between ATP Synthetic Flux and Metabolic Parameters Correlation analyses of rates of ATP synthetic flux (n = 31). (A) Relation between fasting plasma concentration of FFAs and bfATP across all groups. (B) Relation between fasting plasma FFAs and ifATP across all groups. Patients with T2DM (n = 10) (diamonds), age- and BMI-matched controls (CONo; n = 10) (squares), and young healthy controls (CONy; n = 11) (triangles).CC BY · PubMed Central
Figure 5 Glucose Metabolism and ATP Synthetic Flux during Hyperglycemic–Hyperinsulinemia in T2DM Whole body glucose disposal (A), concentration of intramyocellular G-6-P (B), and ifATP (C) during euglycemic (approximately 5.5 mM glucose)–hyperinsulinemic (approximately 500 pM insulin) (white columns) and hyperglycemic (approximately 9.5 mM glucose)–hyperinsulinemic (approximately 500 pM insulin) clamps (hatched columns) in patients with T2DM (n = 4). * p < 0.05.
Figure 5 Glucose Metabolism and ATP Synthetic Flux during Hyperglycemic–Hyperinsulinemia in T2DM Whole body glucose disposal (A), concentration of intramyocellular G-6-P (B), and ifATP (C) during euglycemic (approximately 5.5 mM glucose)–hyperinsulinemic (approximately 500 pM insulin) (white columns) and hyperglycemic (approximately 9.5 mM glucose)–hyperinsulinemic (approximately 500 pM insulin) clamps (hatched columns) in patients with T2DM (n = 4). * p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 47

  1. Krssak, 1999, Diabetologia, 42, 113
  2. Roden, 1996, J Clin Invest, 97, 2859
  3. Goodpaster, 2001, J Clin Endocrinol Metab, 86, 5755
  4. Pruchnic, 2004, Am J Physiol Endocrinol Metab, 287, E857
  5. Lowell, 2005, Science, 307, 384
  6. Roden, 2005, Int J Obes (Lond), 29, S111
  7. Stump, 2003, Proc Natl Acad Sci U S A, 100, 7996
  8. Ritov, 2005, Diabetes, 54, 8
  9. Kelley, 2002, Diabetes, 51, 2944
  10. Lebon, 2001, J Clin Invest, 108, 733
  11. Petersen, 2003, Science, 300, 1140
  12. Petersen, 2004, N Engl J Med, 350, 664
  13. Brehm, 2006, Diabetes, 55, 136
  14. Baecke, 1982, Am J Clin Nutr, 36, 936
  15. Stingl, 2001, Diabetologia, 44, 48
  16. Jucker, 2000, Proc Natl Acad Sci U S A, 97, 6880
  17. Krebs, 2001, J Clin Endocrinol Metab, 86, 2153
  18. Mandarino, 1993, Am J Physiol, 265, E898
  19. Hother-Nielsen, 1993, Metabolism, 42, 86
  20. Simoneau, 1997, J Appl Physiol, 83, 166
  21. Halvatsiotis, 2002, Diabetes, 51, 2395
  22. Short, 2005, Proc Natl Acad Sci U S A, 102, 5618
  23. Gollnick, 1972, J Appl Physiol, 33, 312
  24. Jezek, 1998, Biochim Biophys Acta, 1365, 319
  25. Wojtczak, 1993, Biochim Biophys Acta, 1183, 41
  26. Wellen, 2005, J Clin Invest, 115, 1111
  27. Maassen, 2004, Diabetes, 53, S103
  28. Richardson, 2005, J Biol Chem, 280, 10290
  29. Huang, 1999, Diabetes, 48, 1508
  30. Sreekumar, 2002, Diabetes, 51, 1913
  31. da-Silva, 2004, J Biol Chem, 279, 39846
  32. Cline, 1999, N Engl J Med, 341, 240
  33. Bonadonna, 1996, Diabetes, 45, 915
  34. Rothman, 1995, Proc Natl Acad Sci U S A, 92, 983
  35. Rothman, 1992, J Clin Invest, 89, 1069
  36. Yki-Jarvinen, 1990, Metabolism, 39, 859
  37. Perseghin, 1996, N Engl J Med, 335, 1357
  38. Bogardus, 1984, J Clin Invest, 73, 1185
  39. Damsbo, 1991, Diabetologia, 34, 239
  40. Shulman, 1990, N Engl J Med, 322, 223
  41. Nair, 2005, Am J Clin Nutr, 81, 953
  42. Rasmussen, 2003, Pflugers Arch, 446, 270
  43. Ferrannini, 1996, Diabetes, 45, 947
  44. Fink, 1986, J Clin Invest, 77, 2034
  45. Fink, 1983, J Clin Invest, 71, 1523
  46. Roden, 1999, Diabetes, 48, 358
  47. Roden, 2006, Nat Clin Pract Endocrinol Metab, 2, 335

Cited by

See all 243

Metadata

Authors
Szendroedi, J., Schmid, A. I., Chmelik, M., Toth, C., Brehm, A., Krssak, M., Nowotny, P., Wolzt, M., Waldhausl, W., & Roden, M.
Affiliations
  • University of Vienna (AT)
  • Medical University of Vienna (AT)
  • Hanusch Hospital (AT)
Corresponding author
Roden, Michael
Venue
PLoS Medicine
Published
2007-05-01
Volume
4
Issue
5
Pages
e154
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W1969753458
Cited by
243
References
48
Citations by year
2026: 4 · 2025: 3 · 2024: 5 · 2023: 11 · 2022: 7 · 2021: 13 · 2020: 6 · 2019: 4 · 2018: 14 · 2017: 10 · 2016: 11 · 2015: 12 · 2014: 19 · 2013: 13 · 2012: 20
FWCI
9.00
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • European Foundation for the Study of Diabetes
  • Universität Wien
  • Oesterreichische Nationalbank (OENB 11459)
  • Novo Nordisk
  • Medizinische Universität Wien
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
type 2 diabetes, skeletal muscle, mitochondrial ATP production, glucose-6-phosphate, insulin resistance, insulin sensitivity, intramyocellular lipid, free fatty acids, 31P NMR, glycogen synthesis, hyperinsulinemia
MeSH terms
Adenosine Triphosphate, Adipose Tissue, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Female, Humans, Insulin Resistance, Male, Middle Aged, Mitochondria, Muscle, Magnetic Resonance Spectroscopy, Obesity, Phosphorylation, Glucose Clamp Technique, Glucose-6-Phosphate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Muscle Mitochondrial ATP Synthesis and Glucose Transport/Phosphorylation in Type 2 Diabetes. https://app.cochat.ai/papers/10.1371/journal.pmed.0040154
The paper
Szendroedi, J., Schmid, A. I., Chmelik, M., Toth, C., Brehm, A., Krssak, M., Nowotny, P., Wolzt, M., Waldhausl, W., & Roden, M. (2007). Muscle Mitochondrial ATP Synthesis and Glucose Transport/Phosphorylation in Type 2 Diabetes. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0040154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.